Ritonavir Form III Crystallization via Thermal Nucleation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more consistent and rapid methods to produce crystalline Form III ritonavir, which has promising bioavailability properties, as previous methods were inefficient and unpredictable.
Innovation Solution
A thermal method is developed to convert ritonavir Form II into Form III by melting the sample to a specific temperature within a nucleation range, holding it for a period, and optionally ramping to a second temperature, allowing for the formation of Form III ritonavir.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to produce Form III ritonavir, then the process is simple, but the method is inefficient and unpredictable
Solution Approach 1:
The patent applies parameter changes by precisely controlling temperature parameters during the crystallization process. The method involves heating to a specific temperature range (50-70°C) and maintaining it for a defined period (18-72 hours), transforming the unpredictable traditional approach into a controlled process with consistent results. This temperature parameter optimization directly resolves the contradiction between efficiency and predictability.
Solution Approach 2:
The patent employs preliminary action by preparing the ritonavir sample in a specific state before the crystallization process. The method requires dissolving ritonavir in a hydroalcoholic solution and maintaining specific conditions before initiating the temperature-controlled crystallization. This preliminary preparation ensures that the subsequent process yields predictable Form III crystals, eliminating the unpredictability of traditional methods.
2Speed
If the nucleation temperature is increased to accelerate Form III formation, then the production speed increases, but the control precision becomes more difficult
Solution Approach 1:
The patent resolves this contradiction by optimizing the temperature parameter within a specific range (50-70°C) rather than using extreme temperatures. This moderate temperature range accelerates crystallization compared to traditional methods while remaining easy to control with standard laboratory equipment. The defined temperature window balances speed and controllability, allowing consistent Form III formation without requiring ultra-precise temperature control systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of Form III ritonavir in a controlled and efficient manner, suitable for pharmaceutical applications, with improved bioavailability and stability.
Implementation Method 1
melting a sample of ritonavir; melting the sample to a specific temperature within a nucleation range
Implementation Method 2
cooling the sample to a first temperature within a nucleation temperature range
Implementation Method 3
holding the sample at one or more temperatures within the nucleation temperature range for a sufficient period to obtain crystalline Form III ritonavir
Data Source
AI summary
The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.